ICIcaro Rodrigo Dutra Cunha

Icaro Rodrigo Dutra Cunha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Icaro Rodrigo Dutra Cunha has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic Potential of Fridericia platyphylla (Cham.) L.G. Lohmann: An Integrative Review of the Effects of Crude Extracts and Isolated Phytochemicals in Different Experimental Models

    by Andressa Coelho Ferreira, Raphael Furtado Marques, Icaro Rodrigo Dutra Cunha, Jhonata Costa Moura, Rebekha Matos Oliveira, Kellen De Jesus Farias Da Luz, Ludmila Tavares dos Santos Silva, Mateus Balbino Barbosa de Carvalho, Lara Possapp Andrade, Júlia Karla de Albuquerque Melo Xavier, et al.

    Fridericia platyphylla (Cham.) L.G. Lohmann is a species endemic to the Brazilian Cerrado, commonly known as “cervejinha do campo,” “cipó-una,” or ‘tintureiro,” traditionally used to treat kidney stones and joint pain. This species has garnered scientific interest due to its potential pharmacological properties. This review evaluated the pharmacological effects of crude extracts and isolated compounds from F. platyphylla, as well as its ethnopharmacological relevance. A comprehensive literature search was conducted across PubMed, Scielo, and Google Scholar for studies published between October 2014 and December 2024, using the descriptors “F. platyphylla” and “A. brachypoda” combined with terms related to in vivo, in vitro, and ethnopharmacological research. Of 896 records, 20 studies met the inclusion criteria. The included studies conducted comprehensive isolation and structural elucidation of the bioactive compounds, confirming their chemical identities and supporting their pharmacological relevance through robust analytical and spectroscopic validation. Different extracts and isolated compounds from the roots, leaves, and flowers of F. platyphylla have antiulcerogenic, antitumor, antiproliferative, anti-inflammatory, and antifungal action. Brachydins demonstrated cytotoxicity against prostate cancer cells and exhibited biological potential against intracellular amastigotes of Trypanosoma cruzi. Luteolin reduced proliferation in U-251 glioblastoma cells with low toxicity to nontumor cells. Additionally, the microemulsion and encapsulation of the active fraction obtained from the roots of this plant showed relevant biological activity for pharmaceutical applications. However, despite these promising findings, potential mutagenic effects raise concerns about the safety of using the plant. In conclusion, F. platyphylla and its phytochemicals hold significant therapeutic and technological potential. Nevertheless, further in vivo studies are necessary to ensure safety and better understand its pharmacological mechanisms, thereby paving the way for the development of novel therapeutic agents derived from this species.